Loading

GI INNOVATION

June 16, 2025
Company Presentation
Oncology
GI Innovation, a KOSDAQ-listed biotech, pioneers fusion protein drugs for cancer and allergies. Since 2017, it secured $230 million through funding rounds, IPO, and licensing deals for preclinical and clinical assets. Leveraging global partnerships for rapid development, the leading programs include immuno-oncology assets GI-101, subcutaneous form GI-102, and anti-allergy asset GI-301, alongside other innovative programs, which includes metabolic immuno-oncology asset GI-108
GI INNOVATION
Company HQ City: Seoul
Company HQ Country: Korea, Republic of
Year Founded: 2017
Lead Product in Development: GI-102, GI-101A

CEO

Byunggeon Rhee, Junho Hong

Year Founded

2017

Development Phase of Lead Product

Phase II

Number of Unlicensed Products Looking for Licensing

3

Exchange

KOSDAQ

Ticker

A358570

When you expect your next catalyst update?

Licensing out

What is your next catalyst (value inflection) update?

first half of this year

Website

https://www.gi-innovation.com/en/
Primary Speaker
Nari Yun
Nari Yun, PhD
Head of clinical/Strategy
GI Innovation

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS